ArticleNature communications2025
Engineering HLA-G-targeted extracellular vesicles nanoplatform for enhanced cancer therapy through precise cancer drug delivery.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Mechanisms of microRNA export in mammalian cells: From random release to selective secretion.The Journal of biological chemistry · 2026Review
- 3D-printed dictamni-calcium silicate scaffolds modulate the osteoimmune microenvironment and enhance macrophage-derived exosomal miR-21 signaling in vascularized bone regeneration.Journal of nanobiotechnology · 2026Article
- Engineering integrin αvβ8-targeted extracellular vesicles to deliver BDNF mRNA for motor recovery in spinal cord injury.Journal of nanobiotechnology · 2026Article
- Bioengineering of extracellular vesicles with scaffold proteins for drug delivery.Journal of nanobiotechnology · 2026Review
- Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Mitochondrial biogenesis modulation by silicon-stimulated mesenchymal stem cells-derived extracellular vesicles drives angio- and lymphangiogenesis in chronic wound healing.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Extracellular vesicles (EVs) hold great potential as a therapeutic delivery system for cancer treatment. Here, we develop an innovative targeted drug delivery platform, human leukocyte antigen-G-VHH antibody-modified EV (α-HLA-G-EV), to enhance therapeutic efficacy. A genetically engineered HEK293T stable clone is utilized to produce α-HLA-G-EV, which are subsequently loaded with chemotherapeutic agents to create HLA-G-targeting drug-loaded EVs (drug@α-HLA-G-EV). The cytotoxicity of drug@α-HLA-G-EV is assessed in various cancer cell lines, demonstrating superior tumor targeting and therapeutic efficacy compared to standard chemotherapies. In vivo experiments using xenograft NPG mouse models, established with MDA-MB-231 and U87 cell lines, further confirm the enhanced antitumor activity of Doxorubicin@α-HLA-G-EV and Temozolomide@α-HLA-G-EV. These findings are consistent with results observed in patient-derived breast cancer and GBM cell models. Additionally, drug@α-HLA-G-EV causes far less damage to normal organs than Lipo-Dox. These findings highlight the potential of α-HLA-G-EV as a versatile platform for precise and efficient cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.